Damora Therapeutics Inc — Current Report (Form 8-K)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 17, 2026

DAMORA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Damora Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders on June 17, 2026 (the “Annual Meeting”). The following proposals were submitted to the stockholders of the Company at the Annual Meeting, which are described in detail in the the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2026 (the “Proxy Statement”):

There were 60,303,212 shares of Common Stock outstanding and entitled to vote on April 22, 2026, the record date for the Annual Meeting, and 55,009,938 shares of Common Stock were represented in person or by proxy at the Annual Meeting, which number constituted a quorum.

At the Annual Meeting, each of the Company’s director nominees was elected, a frequency of one year received the plurality of votes cast on the Say-on-Frequency Proposal and the other proposals voted on were approved. The final voting results regarding each proposal are set forth below.

In light of these voting results and in accordance with its prior recommendation, the Board has determined that the Company will hold future Say-on-Pay votes every year until the next required Say-on-Frequency vote.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.